Business context and reporting period
Filing identity: The supplied filing is ReShape Lifesciences Inc.’s Form 10-K for the fiscal year ended December 31, 2022, not a Vyome Holdings, Inc. filing. It compares 2022 with restated 2021 results; it does not provide a standalone 2022 fourth-quarter results summary.
ReShape sells the Lap-Band adjustable gastric band system and offers virtual coaching and wellness products. Its Obalon balloon system was not commercially available, and its diabetes neuromodulation device remained in development. Lap-Band accounted for nearly all revenue.
Financial results and liquidity
| Metric | 2022 | 2021, restated | Change |
|---|---|---|---|
| Revenue | $11.24 million | $13.60 million | Down 17.4% |
| Gross profit / margin | $6.80 million / 60.5% | $8.35 million / 61.4% | Gross profit down 18.5% |
| Operating loss | $46.35 million | $57.88 million | Loss narrowed |
| Net loss | $46.21 million | $63.15 million | Loss narrowed |
| Net cash used in operating activities | $21.90 million | $15.38 million | Cash use increased |
- Sales and marketing expense rose to $14.09 million from $8.89 million, principally reflecting direct-to-consumer advertising. General and administrative expense declined to $17.25 million from $24.32 million, largely due to lower stock-based compensation and merger-related costs.
- The company recorded $18.74 million of impairment charges in 2022, including impairments of ReShape Vest, Lap-Band and Obalon-related assets. The 2021 comparison included a $30.65 million impairment charge.
- At year-end, cash and cash equivalents were $3.86 million, restricted cash was $0.10 million, working capital was approximately $2.4 million, and total current liabilities were $7.48 million. The company reported no outstanding debt at year-end.
- On February 8, 2023, ReShape raised approximately $10.2 million gross, or approximately $9.4 million net, through a public offering of shares or pre-funded warrants and warrants.
Material changes, outlook, and key risks
- Revenue fell across all reported geographies. Management attributed the decline primarily to bariatric-center closures during the Omicron surge from late 2021 into early 2022; U.S. revenue declined 10.4% and European revenue declined 41.1%.
- Under CEO Paul Hickey, appointed in August 2022, the company shifted toward targeted digital and regional marketing and cost discipline. Management reported that patient lead costs in the third and fourth quarters were more than 50% below the second quarter.
- Management anticipated 2023 revenue opportunities from Calibration Tubes and ReShapeCare. It expected to file Lap-Band 2.0 with the FDA in the first half of 2023 and receive FDA feedback by year-end; these are expectations, not assured outcomes. ReShape also planned to assess partners for a possible Obalon relaunch. No quantified financial guidance was provided.
- Management expects a net loss and negative operating cash flow in 2023. The auditor and management identified substantial doubt about the company’s ability to continue as a going concern; management stated the financing and operating plans do not alleviate that doubt.
- The company restated 2021 annual and multiple 2021–2022 interim financial statements. Corrections included improper capitalization of a $1.9 million D&O tail insurance policy, stock-option valuation and share-count errors, tax disclosure and valuation-allowance matters, and a legal accrual. Previously issued statements for the affected periods should no longer be relied upon.
- Management concluded internal control over financial reporting was ineffective at December 31, 2022, citing material weaknesses involving accounting resources, purchase accounting, income taxes, journal-entry approvals, and IT access and change management. Remediation was underway.
- The SEC Division of Enforcement had opened an informal inquiry related to a late-filing notice for the second-quarter 2022 Form 10-Q. The company said the inquiry could lead to penalties or other sanctions; its outcome was uncertain.
- Other notable exposures include the Cowen judgment for $1.35 million plus statutory interest and attorneys’ fees, a filed patent-infringement suit against Allurion, and an FDA request for additional information about Lap-Band adverse-event reports involving pregnancy. The company also disclosed that deposits exceeded FDIC insurance limits after the March 2023 SVB closure.
Most important facts for investors to verify
- Confirm the filing issuer: the document identifies ReShape Lifesciences Inc., whereas the request metadata names Vyome Holdings, Inc.
- Review the restatement notes and corrected interim statements, and assess the scope and progress of internal-control remediation.
- Assess cash runway against operating cash burn, the February 2023 offering proceeds, and management’s going-concern warning; verify current cash availability and uninsured bank exposure.
- Track Lap-Band sales, gross margin, and whether planned Calibration Tube and ReShapeCare revenue develops as expected.
- Monitor FDA developments for Lap-Band and Lap-Band 2.0, progress toward any Obalon relaunch, and the status of the DBSN development program.
- Follow the SEC inquiry, Cowen judgment and related accruals, Allurion litigation, and FDA pregnancy-related request for information.